Statistics

Total Visits

Views
Tenofovir DF prevents HBV reactivation in anti-HBc positive patients with hematologic malignancies treated with Rituximab: 12-months results of a randomized study (PREBLIN study)52

Select a period of time:

Number of views in the range

Views
Tenofovir DF prevents HBV reactivation in anti-HBc positive patients with hematologic malignancies treated with Rituximab: 12-months results of a randomized study (PREBLIN study)36

Views

Views
March 202516
April 20252
May 20250
June 20251
July 202514
August 20253
September 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States10
Brazil5
Argentina1
Germany1
Spain1
Hong Kong1
South Africa1
 

Top cities views

Views
Dallas4
Caxias do Sul2
Cape Town1
Carpentersville1
Council Bluffs1
Guaratinguetá1
Hamburg1
Hong Kong1
Miami1
Nova Friburgo1